# Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia

> **NCT05509595** · PHASE2 · COMPLETED · sponsor: **National Institute of Dental and Craniofacial Research (NIDCR)** · enrollment: 12 (actual)

## Conditions studied

- Fibrous Dysplasia Of Bone

## Interventions

- **DRUG:** Burosumab

## Key facts

- **NCT ID:** NCT05509595
- **Lead sponsor:** National Institute of Dental and Craniofacial Research (NIDCR)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-07
- **Primary completion:** 2024-11-18
- **Final completion:** 2024-11-18
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05509595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05509595, "Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05509595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*